{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:32:27Z","timestamp":1787506347284,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40265-021-01516-y","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T06:03:02Z","timestamp":1621317782000},"page":"1101-1105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Evinacumab: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"1516_CR1","unstructured":"Regeneron Pharmaceuticals. FDA approves first-in-class EVKEEZATM (evinacumab-dgnb) for patients with ultra-rare inherited form of high cholesterol [media release]. 11 Feb 2021. https:\/\/investor.regeneron.com."},{"key":"1516_CR2","unstructured":"Regeneron Pharmaceuticals. Regeneron pipeline. 2021. https:\/\/www.regeneron.com\/pipeline. Accessed 30 Mar 2021."},{"issue":"3","key":"1516_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1705994","volume":"377","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296\u20137.","journal-title":"N Engl J Med."},{"issue":"8","key":"1516_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med."},{"key":"1516_CR5","unstructured":"Regeneron Pharmaceuticals. EVKEEZA\u2122 (evinacumab-dgnb) injection: US prescribing information. 2021. https:\/\/www.regeneron.com\/sites\/default\/files\/Evkeeza_PI.pdf. Accessed 15 Feb 2021."},{"key":"1516_CR6","unstructured":"European Medicines Agency. Evkeeza (evinacumab): summary of opinion (initial authorisation). 2021. https:\/\/www.ema.europa.eu\/. Accessed 27 Apr 2021."},{"key":"1516_CR7","unstructured":"Regeneron Pharmaceuticals. Regeneron initiates major global collaboration with Sanofi-Aventis to develop and commercialize fully-human therapeutic antibodies [media release]. 29 Nov 2007. http:\/\/www.regeneron.com."},{"key":"1516_CR8","doi-asserted-by":"crossref","unstructured":"Sanofi Aventis. Sanofi-Aventis and Regeneron expand strategic antibody collaboration [media release]. 11 Nov 2009. http:\/\/www.sanofi-aventis.com.","DOI":"10.3833\/pdr.v2009i11.1274"},{"issue":"7","key":"1516_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1194\/jlr.M054890","volume":"56","author":"V Gusarova","year":"2015","unstructured":"Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56(7):1308\u201317.","journal-title":"J Lipid Res."},{"key":"1516_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2020.10.013","volume":"314","author":"M Harada-Shiba","year":"2020","unstructured":"Harada-Shiba M, Ali S, Gipe DA, et al. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis. 2020;314:33\u201340.","journal-title":"Atherosclerosis"},{"issue":"Suppl 3","key":"1516_CR11","first-page":"A14407","volume":"142","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. The longer-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia [abstract no. 14407]. Circulation. 2020;142(Suppl 3):A14407.","journal-title":"Circulation"},{"issue":"24","key":"1516_CR12","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307\u201319.","journal-title":"N Engl J Med."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01516-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01516-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01516-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T07:43:19Z","timestamp":1624261399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01516-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01516-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"30 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Changes resulting from any comments received during the peer review process were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}